Skip to Main Content

Paper Details

Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models.
PNAS Nexus
2
2022
ATF4, BC, Cas9, NOXA, PDXs, RTKs, TAK-243, TNBC, TNBC lines, TNBC models, TNBCs, Triple negative breast cancer, UBA1, activating transcription factor 4, breast cancer, c, c-MYC, normal tissue-derived cells, patient, patient derived xenograft models, receptor tyrosine kinases, triple negative breast cancer, tumor, tyrosine, ubiquitin, ubiquitin-like modifier activating enzyme 1
Author NameAffiliation
Mikhail G DozmorovVirginia Commonwealth University
Joshua Chuck HarrellVirginia Commonwealth University School of Medicine
Joshua Chuck HarrellWright Center for Clinical and Translational Research, Virginia Commonwealth University School of Medicine
Joshua Chuck HarrellVirginia Commonwealth University
Cyril H BenesCenter for Cancer Research, Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School
  • 1 - 5

Datasets

Release 1.2